August 2011

Johan Lennartsson's research focuses on platelet-derived growth factor receptor (PDGFR) and mitogen-activated protein kinase (MAPK) signaling in normal physiology and cancer.

The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.

The 2 upcoming conferences include the 7th Annual Multidisciplinary Symposium on Head and Neck Cancer and the School of Breast Oncology.

It's hard to tell which moves more quickly: Edith Perez's feet, or her mind.

Biological markers that help clinicians choose which treatment options to pursue for particular patients are attracting increased research interest.

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.

As personalized medicine occupies a growing role in the pharmaceutical pipeline, major companies are changing their research and development paradigms.

The oncology community is quite conversant with the clinical utility of prognostic tumor markers.